Literature DB >> 33694155

Halofuginone, a promising drug for treatment of pulmonary hypertension.

Pritesh P Jain1, Tengteng Zhao1, Mingmei Xiong1,2, Shanshan Song, Ning Lai1,3, Qiuyu Zheng4, Jiyuan Chen1,3, Shane G Carr, Aleksandra Babicheva1, Amin Izadi1, Marisela Rodriguez1, Shamin Rahimi1, Francesca Balistrieri1, Shayan Rahimi1, Tatum Simonson1, Daniela Valdez-Jasso5, Patricia A Thistlethwaite6, John Y-J Shyy7, Jian Wang1,3, Ayako Makino4, Jason X-J Yuan1.   

Abstract

BACKGROUND AND
PURPOSE: Halofuginone is a febrifugine derivative originally isolated from Chinese traditional herb Chang Shan that exhibits anti-hypertrophic, anti-fibrotic and anti-proliferative effects. We sought to investigate whether halofuginone induced pulmonary vasodilation and attenuates chronic hypoxia-induced pulmonary hypertension (HPH). EXPERIMENTAL APPROACH: Patch-clamp experiments were conducted to examine the activity of voltage-dependent Ca2+ channels (VDCCs) in pulmonary artery smooth muscle cells (PASMCs). Digital fluorescence microscopy was used to measure intracellular Ca2+ concentration in PASMCs. Isolated perfused and ventilated mouse lungs were used to measure pulmonary artery pressure (PAP). Mice exposed to hypoxia (10% O2 ) for 4 weeks were used as model of HPH for in vivo experiments. KEY
RESULTS: Halofuginone increased voltage-gated K+ (Kv ) currents in PASMCs and K+ currents through KCNA5 channels in HEK cells transfected with KCNA5 gene. HF (0.03-1 μM) inhibited receptor-operated Ca2+ entry in HEK cells transfected with calcium-sensing receptor gene and attenuated store-operated Ca2+ entry in PASMCs. Acute (3-5 min) intrapulmonary application of halofuginone significantly and reversibly inhibited alveolar hypoxia-induced pulmonary vasoconstriction dose-dependently (0.1-10 μM). Intraperitoneal administration of halofuginone (0.3 mg·kg-1 , for 2 weeks) partly reversed established PH in mice. CONCLUSION AND IMPLICATIONS: Halofuginone is a potent pulmonary vasodilator by activating Kv channels and blocking VDCC and receptor-operated and store-operated Ca2+ channels in PASMCs. The therapeutic effect of halofuginone on experimental PH is probably due to combination of its vasodilator effects, via inhibition of excitation-contraction coupling and anti-proliferative effects, via inhibition of the PI3K/Akt/mTOR signalling pathway.
© 2021 The British Pharmacological Society.

Entities:  

Keywords:  Ca2+ channel; K+ channel; KCNA5; Pulmonary arterial hypertension; halofuginone; smooth muscle cell; treatment

Year:  2021        PMID: 33694155     DOI: 10.1111/bph.15442

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

2.  Heterozygous Tropomodulin 3 mice have improved lung vascularization after chronic hypoxia.

Authors:  Tsering Stobdan; Pritesh P Jain; Mingmei Xiong; Vineet Bafna; Jason X-J Yuan; Gabriel G Haddad
Journal:  Hum Mol Genet       Date:  2022-03-31       Impact factor: 6.150

3.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

4.  Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension.

Authors:  Ziyi Wang; Jiyuan Chen; Aleksandra Babicheva; Pritesh P Jain; Marisela Rodriguez; Ramon J Ayon; Keeley S Ravellette; Linda Wu; Francesca Balistrieri; Haiyang Tang; Xiaomin Wu; Tengteng Zhao; Stephen M Black; Ankit A Desai; Joe G N Garcia; Xin Sun; John Y-J Shyy; Daniela Valdez-Jasso; Patricia A Thistlethwaite; Ayako Makino; Jian Wang; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2021-10-20       Impact factor: 5.282

5.  Combined intermittent and sustained hypoxia is a novel and deleterious cardio-metabolic phenotype.

Authors:  Xin Zhen; Esteban A Moya; Mary Gautane; Huayi Zhao; Elijah S Lawrence; Wanjun Gu; Laura A Barnes; Jason X-J Yuan; Pritesh P Jain; Mingmei Xiong; Pablo Catalan Serra; Luu V Pham; Atul Malhotra; Tatum S Simonson; Omar A Mesarwi
Journal:  Sleep       Date:  2022-06-13       Impact factor: 6.313

6.  TRPC6, a therapeutic target for pulmonary hypertension.

Authors:  Pritesh P Jain; Ning Lai; Mingmei Xiong; Jiyuan Chen; Aleksandra Babicheva; Tengteng Zhao; Sophia Parmisano; Manjia Zhao; Cole Paquin; Moreen Matti; Ryan Powers; Angela Balistrieri; Nick H Kim; Daniela Valdez-Jasso; Patricia A Thistlethwaite; John Y-J Shyy; Jian Wang; Joe G N Garcia; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-27       Impact factor: 6.011

7.  Mechanosensitive channel Piezo1 is required for pulmonary artery smooth muscle cell proliferation.

Authors:  Jiyuan Chen; Marisela Rodriguez; Jinrui Miao; Jing Liao; Pritesh P Jain; Manjia Zhao; Tengteng Zhao; Aleksandra Babicheva; Ziyi Wang; Sophia Parmisano; Ryan Powers; Moreen Matti; Cole Paquin; Zahra Soroureddin; John Y-J Shyy; Patricia A Thistlethwaite; Ayako Makino; Jian Wang; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-03-23       Impact factor: 6.011

Review 8.  Advances in Immunosuppressive Agents Based on Signal Pathway.

Authors:  Zhiqing Xu; Ming Chu
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 9.  Exosomes: A novel insight into traditional Chinese medicine.

Authors:  Chao Mo; Jie Zhao; Jingyan Liang; Huiling Wang; Yu Chen; Guodong Huang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.